Health · 1 sources covering this

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/cfdf4ef0d35e2d40f4cb6cc171492cee54e745a7"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment"></iframe>

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

How 1 sources are covering this

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

More from Health

FDA to require notice of additives in food supply for the first time

STAT+: Ban prior auth? And hospitals cut jobs

STAT+: FDA panel to weigh Grail’s Galleri test

STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

More from Health

FDA to require notice of additives in food supply for the first time

STAT+: Ban prior auth? And hospitals cut jobs

STAT+: FDA panel to weigh Grail&#8217;s Galleri test

STAT+: Pharmalittle: We&#8217;re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

Reader

Trust & legal

Across the network

STAT+: FDA panel to weigh Grail’s Galleri test

STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more